NPM1 and acute myeloid leukemia: Furthermore, the combination of nivolumab and AZA with or without the monoclonal antibody Ipilimumab has been tested in patients with R/R or ND AML, including patients harboring NPM1 mutations, with variable responses and outcomes, along with significant toxicity (NCT02397720).